MedTrace Logo

Post-marketing Surveillance (Special Use-results Surveillance) on Use With Liraglutide (Victoza®)

NCT02321878 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1092

Last updated 2017-09-01

No results posted yet for this study

Summary

This trial is conducted in Asia. The aim of this trial is to evaluate safety and effectiveness of Victoza® in patients with type 2 diabetes mellitus (T2DM) in combination with antidiabetes agents other than sulfonylurea under post-marketing normal clinical practice conditions.

Conditions

Interventions

DRUG

liraglutide

Liraglutide (Victoza®) will be prescribed by the physician under normal clinical practice conditions. No treatment given.

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-15
Primary Completion
2017-06-16
Completion
2017-06-16

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02321878 on ClinicalTrials.gov